Loading...
OTCM
PETV
Market cap29mUSD
Oct 08, Last price  
0.78USD
1D
-4.71%
1Q
-2.57%
Jan 2017
-51.29%
IPO
94.85%
Name

PetVivo Holdings Inc

Chart & performance

D1W1MN
OTCM:PETV chart
P/E
—
P/S
25.91
EPS
—
Div yield, %
—
Shrs. gr., 5y
37.22%
Rev. gr., 5y
146.37%
Revenues
1m
+0.80%
0000075,0007,1241,51077,9363,58812,578115,586917,162968,7061,132,5331,141,607
Net income
-10m
L+24.70%
-263,440-102,630-86,210-36,992,771-1,565,692-3,651,744-15,531,533-2,337,338-4,757,758-2,114,919-3,751,375-4,941,782-8,701,764-10,955,295-8,399,166-10,473,672
CFO
-6m
L+14.76%
-172,424-49,344-70,512-219,135-398,475-690,330-143,017-579,153-736,445-496,589-1,047,329-4,174,957-6,794,483-7,419,588-5,321,953-6,107,286

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. Its flagship product is Spryng, an intra-articular injection administered by veterinarians to effectively alleviate lameness and joint conditions, such as osteoarthritis, in canines and equines. The company's development pipeline further includes seventeen therapeutic devices poised for both veterinary and human clinical applications. Founded in 2009, PetVivo Holdings, Inc. maintains its corporate headquarters in Minneapolis, Minnesota.

Key people

Garry Lowenthal
Chief Financial Officer · since 2024
John Dolan
Chief Business Development Officer, General Counsel · since 2023
John Lai
President, Chief Executive Officer, Director · since 2019
Spencer Breithaupt
Independent Director · since 2023
Robert Costantino
Independent Director · since 2022
Michael Eldred
Independent Director · since 2024
Joseph Jasper
Independent Director · since 2018
Diane Levitan
Independent Director · since 2023
Independent Chairman of the Board · since 2024
IPO date
Jul 10, 2012
Employees
25
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT